162 related articles for article (PubMed ID: 37702177)
1. Innovative Genoceuticals in Human Gene Therapy Solutions: Challenges and Safe Clinical Trials of Orphan Gene Therapy Products.
Sharma R
Curr Gene Ther; 2024; 24(1):46-72. PubMed ID: 37702177
[TBL] [Abstract][Full Text] [Related]
2. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
Drugs R D; 2007; 8(3):176-87. PubMed ID: 17472413
[TBL] [Abstract][Full Text] [Related]
3. Marketing Regulatory Oversight of Advanced Therapy Medicinal Products (ATMPs) in Europe: The EMA/CAT Perspective.
Salmikangas P; Schuessler-Lenz M; Ruiz S; Celis P; Reischl I; Menezes-Ferreira M; Flory E; Renner M; Ferry N
Adv Exp Med Biol; 2015; 871():103-30. PubMed ID: 26374215
[TBL] [Abstract][Full Text] [Related]
4. Comparison of regulatory pathways for the approval of advanced therapies in the European Union and the United States.
Iglesias-Lopez C; Obach M; Vallano A; Agustí A
Cytotherapy; 2021 Mar; 23(3):261-274. PubMed ID: 33483292
[TBL] [Abstract][Full Text] [Related]
5. Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy.
Michaeli DT; Michaeli T; Albers S; Boch T; Michaeli JC
Eur J Health Econ; 2023 Nov; ():. PubMed ID: 37962724
[TBL] [Abstract][Full Text] [Related]
6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
7. Licensing of Orphan Medicinal Products-Use of Real-World Data and Other External Data on Efficacy Aspects in Marketing Authorization Applications Concluded at the European Medicines Agency Between 2019 and 2021.
Naumann-Winter F; Wolter F; Hermes U; Malikova E; Lilienthal N; Meier T; Kalland ME; Magrelli A
Front Pharmacol; 2022; 13():920336. PubMed ID: 36034814
[No Abstract] [Full Text] [Related]
8. Efaproxiral: GSJ 61, JP 4, KDD 86, RS 4, RSR 13.
Drugs R D; 2005; 6(3):178-85. PubMed ID: 15869322
[TBL] [Abstract][Full Text] [Related]
9. Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab.
BioDrugs; 2003; 17(4):290-5. PubMed ID: 12899647
[TBL] [Abstract][Full Text] [Related]
10. Efficacy, safety and cost of gene therapy medicinal products in the U.S. and Europe.
Balkhi B
Drugs Today (Barc); 2022 May; 58(5):223-240. PubMed ID: 35535814
[TBL] [Abstract][Full Text] [Related]
11. INGN 201: Ad-p53, Ad5CMV-p53, Adenoviral p53, INGN 101, p53 gene therapy--Introgen, RPR/INGN 201.
BioDrugs; 2003; 17(3):216-22. PubMed ID: 12749760
[TBL] [Abstract][Full Text] [Related]
12. Oblimersen: Augmerosen, BCL-2 antisense oligonucleotide - Genta, G 3139, GC 3139, oblimersen sodium.
Drugs R D; 2007; 8(5):321-34. PubMed ID: 17767397
[TBL] [Abstract][Full Text] [Related]
13. The Regulation of Cell Therapy and Gene Therapy Products in Switzerland.
Bukovac PK; Hauser M; Lottaz D; Marti A; Schmitt I; Schochat T
Adv Exp Med Biol; 2023; 1430():41-58. PubMed ID: 37526841
[TBL] [Abstract][Full Text] [Related]
14. Drugs for rare diseases: mixed assessment in Europe.
Prescrire Int; 2007 Feb; 16(87):36-42. PubMed ID: 17323539
[TBL] [Abstract][Full Text] [Related]
15. [Scientific advice by the nationally competent authority and by the EMEA on the conduct of clinical trials].
Dejas-Eckertz P; Schäffner G
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Apr; 48(4):423-8. PubMed ID: 15830253
[TBL] [Abstract][Full Text] [Related]
16. Availability, accessibility and delivery to patients of the 28 orphan medicines approved by the European Medicine Agency for hereditary metabolic diseases in the MetabERN network.
Heard JM; Vrinten C; Schlander M; Bellettato CM; van Lingen C; Scarpa M;
Orphanet J Rare Dis; 2020 Jan; 15(1):3. PubMed ID: 31907071
[TBL] [Abstract][Full Text] [Related]
17. FDA orphan products clinical trial grants: assessment of outcomes and impact on rare disease product development.
Miller KL; Mueller C; Liu G; Miller Needleman KI; Maynard J
Orphanet J Rare Dis; 2020 Sep; 15(1):234. PubMed ID: 32883327
[TBL] [Abstract][Full Text] [Related]
18. Requirements for Clinical Trials with Gene Therapy and Transplant Products in Switzerland.
Marti A
Adv Exp Med Biol; 2015; 871():131-45. PubMed ID: 26374216
[TBL] [Abstract][Full Text] [Related]
19. The European landscape for gene therapies in orphan diseases: 6-year experience with the EMA Committee for Orphan Medicinal Products.
Palomo GM; Pose-Boirazian T; Naumann-Winter F; Costa E; Duarte DM; Kalland ME; Malikova E; Matusevicius D; Vitezic D; Larsson K; Magrelli A; Stoyanova-Beninska V; Mariz S
Mol Ther; 2023 Dec; 31(12):3414-3423. PubMed ID: 37794679
[TBL] [Abstract][Full Text] [Related]
20. Orphan drugs, orphan diseases. The first decade of orphan drug legislation in the EU.
Joppi R; Bertele' V; Garattini S
Eur J Clin Pharmacol; 2013 Apr; 69(4):1009-24. PubMed ID: 23090701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
